|
Cost-utility of treatment of the patients with Thalassemia Major in Iran
|
S. Emamgholipour    , B. Ahmadi , A.H. Rajabi , A. Azarkeivan , M. Ebrahimi , F. Esmaeilzadeh |
|
|
| Keywords: Key words: Cost-Benefit Analysis, beta-Thalassemia, Iran |
|
|
Full-Text [PDF 318 kb]
(1748 Downloads)
| Abstract (HTML) (4638 Views)
|
Type of Study: Research |
Subject:
Thalasemia
Published: 2019/01/5
|
|
|
|
|
|
|
Full-Text: (7706 Views) |
References:
- Lazarte SS, Mónaco ME, Terán MM, Haro AC, Achem MEL, Issé BA. Foxo3 gene expression and oxidative status in beta-thalassemia minor subjects. Rev Bras Hematol Hemoter 2017; 39(2): 115-21.
- Azimi A, Alibakhshi R, Hayati H, Tahmasebi S, Alimoradi S. IVS-II-648/649 (-T) (HBB: c. 316-202del) Triggers a Novel β-Thalassemia Phenotype. Hemoglobin 2017; 41(1): 44-6.
- Vincent O, Oluwaseyi B, James B, Saidat L. Coinheritance of Β-Thalassemia and Sickle Cell Anaemia in Southwestern Nigeria. Ethiop J Health Sci 2016; 26(6): 517-22.
- Koh DXR, Raja Sabudin RZA, Mohd Yusoff M, Hussin NH, Ahmad R, Othman A, et al. Molecular Characterisation of α-and β-Thalassaemia among Indigenous Senoi Orang Asli Communities in Peninsular Malaysia. Ann Hum Genet 2017; 81(5): 205-12.
- Muhammad R, Shakeel M, Rehman SU, Lodhi MA. Population-Based Genetic Study of β-Thalassemia Mutations in Mardan Division, Khyber Pakhtunkhwa Province, Pakistan. Hemoglobin 2017; 41(2): 104-9.
- Chiodi E, Nardozza M, Gamberini MR, Pepe A, Lombardi M, Benea G, et al. Left ventricle remodeling in patients with β-thalassemia major. An emerging differential diagnosis with left ventricle noncompaction disease. Clin Imaging 2017; 45: 58-64.
- Fahmey SS, Taha G, EL-Refaey A, Adly S. Skin Disorders in Egyptian Children with β-Thalassemia Major. J Trop Pediatr 2017; 64(2): 104-9.
- Elalfy MS, Aly RH, Azzam H, Aboelftouh K3, Shatla RH, Tarif M, et al. Neurocognitive Dysfunction in Children with B Thalassemia Major: Psychometric, Neurophysiologic and Radiologic Evaluation. Hematology 2017; 22(10): 617-22.
- Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D’Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clin Drug Investig 2017; 37(5): 453-64.
- Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, et al. Prevention of β Thalassemia in Northern Israel-a cost-benefit analysis. Mediterr J Hematol Infect Dis 2014; 6(1): e2014012.
- Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, Akbari Sari A, Yaseri M, Ahmadi B, et al. Economic Burden of Thalassemia Major in Iran, 2015. J Res Health Sci 2016; 16(3): 111-5.
- Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep 2017; 7(1): 920.
- Goulas V, Kourakli-Symeonidis A, Camoutsis C. Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia. ISRN Hematol 2012; 2012: 139862.
- Jagannath VA, Fedorowicz Z, Al Hajeri A, Sharma A. Hematopoietic stem cell transplantation for people with B-thalassaemia major. Cochrane Database Syst Rev 2014; 10: CD008708.
- Porter J, Bowden DK, Economou M, Troncy J, Ganser A, Habr D, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in β-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. Anemia 2012; 2012: 297641.
- Adam S, Afifi H, Thomas M, Magdy P, El-Kamah G. Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt. Hemoglobin 2017; 41(1): 16-20.
- Seyedifar M, Dorkoosh FA, Hamidieh AA, Naderi M, Karami H, Karimi M, et al. Health-related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in
Iran. Int J Hematol Oncol Stem Cell Res 2016; 10(4): 224-31.
- Lai K, Jia S, Yu S, Luo J, He Y. Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence
of fetal hemoglobin. Oncotarget 2017; 8(30): 49931-43.
- Goudarzi R, Zeraati H, Sari AA, Rashidian A, Mohammad K. Population-based preference weights for the EQ-5D health states using the visual analogue scale (VAS) in Iran. Iran Red Crescent Med J 2016; 18(2): e21584.
- Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res 2010; 10(1): 209.
- Hatam N, Esmaelzade F, Mirahmadizadeh A, Keshavarz K, Rajabi A, Afsar Kazerooni P, et al. Cost-effectiveness of rabies post exposure prophylaxis in Iran. J Res Health Sci 2014; 14(2): 122-7.
- Ho WL, Lin KH, Wang JD, Hwang JS, Chung CW, Lin DT, et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant 2006; 37(6): 569-74.
- Sattari MR, Sheykhi D, Nikanfar A, Pourfeiz A, Nazari M, Dolatkhah R, et al. The financial and social impact of thalassemia and its treatment in Iran. Pharm Sci 2012; 18(3): 171-6.
- Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes 2010; 3(1): 29.
- Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B. Cost–utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Transfusion 2013; 53(8): 1722-9.
- Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008; 24(6):1609-21
|
Sci J Iran Blood Transfus Organ 2019; 15(4): 257-264
|
Cost-utility of treatment of the patients with
Thalassemia Major in Iran
Emamgholipour S.1, Ahmadi B.1, Rajabi A.2, Azarkeivan A.3,4,
Ebrahimi M.3,4, Esmaeilzadeh F.5
1School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2Golestan University of Medical Sciences, Gorgan, Iran
3Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
4Adult Thalassemia Clinic, Tehran, Iran
5Department of Public Health, School of Public Health, Maragheh University of Medical Sciences, Maragheh, Iran
Abstract
Background and Objectives
Thalassemia major is an autosomal recessive disease with serious morbidity, mortality and pathology. Due to today’s therapeutic advances, the life expectancy of thalassemia patients has significantly increased. As a result, thalassemia patients need lifelong care, but caring for patients with thalassemia causes a lot of costs. Therefore, being aware of the costs and effectiveness of the treatments is essential for controlling the costs and providing effective treatments.
Materials and Methods
In this cross-sectional descriptive study, a bottom-up method was used to estimate the treatment costs for thalassemia patients and all the costs were estimated over a one-year period (2015). The number of QALYs created by treatment was also extracted using the EQ5D questionnaire, and eventually, the Markov model was used to calculate the costs and effectiveness for patients’ longevity.
Results
Treatment for any patients with thalassemia major costs $ 8,321.8 per year. Applying a 3% discount rate, we estimated that each patient lifelong treatment costs $ 147,098.4, which would results in 11.8 QALYs. Hence, the cost per QALY would be $ 12,466,0.
Conclusions
Treating the patients with thalassemia major, despite its cost effectiveness, might cost a lot so that the treatment of the patients in the fourth decade of their lives may even reach the cost-effectiveness threshold. Therefore, increasing the costs in the field of patient screening and prevention of the birth of patients with thalassemia major seems to be useful.
Key words: Cost-Benefit Analysis, beta-Thalassemia, Iran
Received: 30 Apr 2018
Accepted:14 Aug 2018
Correspondence: Esmaeilzadeh F., PhD in Health Economics. Assistant Professor of Department of Public Health, School of Public Health, Maragheh University of Medical Sciences.
Postal Code: 5515878151, Maragheh, Iran. Tel: (+9841) 37256926; Fax: (+9841) 37256901
E-mail:
firooz.esmaeilzadeh@gmail.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Emamgholipour S, Ahmadi B, Rajabi A, Azarkeivan A, Ebrahimi M, Esmaeilzadeh F. Cost-utility of treatment of the patients with Thalassemia Major in Iran. Sci J Iran Blood Transfus Organ 2018; 15 (4) :257-264 URL: http://bloodjournal.ir/article-1-1193-en.html
|
.jpg)
.png)
